Major step in targeted prostate cancer checks
The UK government has expanded a prostate cancer screening trial to include tens of thousands of black men aged 45 to 74. These men will be invited for testing to help improve early detection methods for the disease.
Health officials say the aim is to find better ways of identifying prostate cancer earlier, especially in high risk groups. Black men face a much higher risk, with studies showing their lifetime chance of developing prostate cancer is about one in four.
Why black men are being prioritised
Prostate cancer remains the most common cancer among men in the UK. Around 64,000 men receive a diagnosis each year, and about 12,000 die from the disease.
Medical data shows black men face double the risk compared to other groups. Because of this, researchers are focusing on targeted screening to close the gap in outcomes and improve survival rates.
What the screening trial includes
The government has committed £18 million to support the Transform trial. The study will test whether combining different methods improves accuracy.
Participants may receive:
- PSA blood tests to detect prostate specific antigen levels
- Genetic testing to identify higher risk variants
- Faster MRI scans for more detailed imaging
Researchers hope this combined approach will reduce missed cases and improve early diagnosis.
Debate over routine screening
Health experts continue to debate routine screening for all men. The UK National Screening Committee recently advised against regular PSA testing for most men without symptoms.
They argue that PSA screening can lead to unnecessary treatment. Some prostate cancers grow slowly and may never cause harm. However, treatment can still lead to serious side effects such as bladder control problems and erectile dysfunction.
For now, men are still encouraged to speak with a doctor if they notice symptoms like difficulty urinating.
A step toward better future screening
Officials believe the expanded trial will help shape a more accurate national screening system in the future. Health leaders say the focus is now on improving precision rather than broad testing.
A health spokesperson said the programme is designed to focus on those most at risk and strengthen research to close evidence gaps.
